Jim Cramer on Recursion: “It Is so Low That It Comes in Under the Category of Speculative”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer discussed, along with the tech battleground. Answering a caller’s query about the stock during the lightning round, Cramer said:

“I’m telling you, I am myself confounded by it. The stock has been horrendous. We gotta put that right on the table. I’m talking about horrendous, okay? So I do not like to recommend horrendous stocks. It is so low that it comes in under the category of speculative. As long as you’re willing to take the pain, they can’t, you know, you said it, they have a lot of money, but wow, I have to tell you, bad taste in my mouth. Bad.”

A stock market chart. Photo by Arturo A on Pexels

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that uses automation, data science, and AI to accelerate drug discovery. The company develops treatments for genetic, infectious, and cancer-related diseases. During the October 20 episode, a caller asked whether the stock is too speculative. In response, the Mad Money host remarked:

“Okay, I had Recursion on when they were 9, 10. They did an equity offering. The stock got clobbered. It’s been down. Now, it’s a meme stock, and I can predict, unfortunately, that when it’s a meme stock, it’s going to go up every day. They’ve adopted this stock. They want to take it higher. I don’t know why, but that’s what they say. And I say they, I’m saying, I see they’re buying early on in the morning. That’s what’s going to happen.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.